Publications by authors named "Rowan Miller"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

38

Total Likes

0

Extended Reach

6,110

Social Features

5
S
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.
James Spicer, Bristi Basu, Ana Montes, Udai Banerji, Rebecca Kristeleit, Rowan Miller, Gareth J Veal, Christopher J Corrigan, Stephen J Till, Mariangela Figini

Nat Commun· July 2023

Videos about Article: user

1 2 4 2 29

View All Article and Social Media Activity
P
P-POSSUM Falls Short: Predicting Morbidity in Ovarian Cancer (OC) Cytoreductive Surgery.
Michail Sideris, Mark R Brincat, Oleg Blyuss, Samuel George Oxley, Jacqueline Sia, Rowan E Miller

Cancers (Basel)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population.
Eve Merry, Ronas Taner Kesmez, Tamara Yu, Michael Flynn, Jonathan Ledermann, Rowan Miller

Int J Gynecol Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study.
Timothy A Yap, Patricia LoRusso, Rowan E Miller, Rebecca Kristeleit, Amanda G Paulovich

Br J Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer.
Uma A Mukherjee, Rowan E Miller, Jonathan A Ledermann

Ther Adv Med Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial.
Rebecca Kristeleit, Michael-John Devlin, Andrew Clamp, Charlie Gourley, René Roux, Rowan E Miller

JAMA Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial.
Toon Van Gorp, Kathleen N Moore, Gottfried E Konecny, Alexandra Leary, Yolanda García-García, Rowan E Miller

Lancet Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current practices for the management of advanced high-grade epithelial ovarian cancer in the UK: OC-NOW survey (2023).
Christina Fotopoulou, Rebecca Bowen, Ranjit Manchanda, Agnieszka Michael, Stephen McCormack, Rowan Miller

Future Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer.
Uma Anne Mukherjee, Helen Hockings, Nicholas Counsell, Apini Patel, Priya Narayanan, Rowan Miller

BMJ Open· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer.
Luke Steventon, Kenneth K C Man, Shibani Nicum, Rowan E Miller, Shira Peleg Hasson

Oncologist· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: A retrospective cohort study.
Luke Steventon, Emma Kipps, Kenneth Kc Man, Rebecca Roylance, Martin D Forster, Rowan E Miller

Eur J Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London.
Karim H El-Shakankery, Joanna Kefas, Kieran Palmer, Andrew Houston, Uma Mukherjee, Rowan E Miller

Cancers (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient decision aids in mainstreaming genetic testing for women with ovarian cancer: A prospective cohort study.
Monika Sobocan, Dhivya Chandrasekaran, Michail Sideris, Oleg Blyuss, Caitlin Fierheller, Rowan E Miller

BJOG· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
Ranjit Manchanda, Li Sun, Monika Sobocan, Isabel V Rodriguez, Xia Wei, Rowan E Miller

J Natl Compr Canc Netw· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy-a role for early monitoring and intervention.
Ellen Nuttall Musson, Rowan E Miller, Marc R Mansour, Michelle Lockley, Jonathan A Ledermann

Leukemia· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, Jubilee Brown, Rowan Miller

Clin Cancer Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
Thierry André, Dominique Berton, Giuseppe Curigliano, Renaud Sabatier, Anna V Tinker, Rowan Miller

JAMA Netw Open· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy.
Georgina E Wood, Christopher P Bunting, Mesel Veli, Rupali Arora, Daniel M Berney, Rowan E Miller

Front Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Landscape of Adoptive Cellular Therapies in Ovarian Cancer.
Lucy Davis, Rowan E Miller, Yien Ning Sophia Wong

Cancers (Basel)· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of PARP inhibitor combination therapy in ovarian cancer.
Helen Hockings, Rowan E Miller

Ther Adv Med Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic testing in high-grade serous ovarian cancer: current options and future development.
Michael-John Devlin, Rowan Miller

Int J Gynecol Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disparity in the era of personalized medicine for epithelial ovarian cancer.
Michael-John Devlin, Rowan E Miller

Ther Adv Med Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
Panagiotis A Konstantinopoulos, Jung-Min Lee, Bo Gao, Rowan Miller, Jung-Yun Lee

Gynecol Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors.
Rowan E Miller, Osnat Elyashiv, Karim H El-Shakankery, Jonathan A Ledermann

Onco Targets Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.
Elizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, Daniel C Cho, Sarah P Blagden, Rowan E Miller

J Immunother Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis